Advertisement


Asaf Maoz, MD, on Li-Fraumeni Syndrome: Multimodality Screening Program

2025 ASCO Annual Meeting

Advertisement

Asaf Maoz, MD, of Dana-Farber Cancer Institute/Mass General Brigham/Harvard Medical School, reviews the results of a prospective study of whole-body magnetic resonance imaging as part of cancer screening for individuals with Li-Fraumeni syndrome (Abstract 10501). 



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Our study evaluated the use of whole-body MRI for individuals with Li-Fraumeni syndrome. Li-Fraumeni syndrome is a cancer predisposition syndrome with a very high risk of cancer, which in some studies has been shown to be up to 100%, and the cancer risk is across different organs and different histologies. A multimodal surveillance program is recommended for individuals with Li-Fraumeni syndrome and that includes a whole-body MRI every year. This is now included in guidelines including NCCN and ACR. But insurance coverage for whole-body MRI has been non-uniform, especially in the United States. Our study was designed to evaluate the ability of whole-body MRI to detect asymptomatic, potentially curable cancers among individuals with Li-Fraumeni syndrome and to measure the proportion of cancers that were diagnosed on whole-body MRI versus other screening modalities. Our study included 162 adult and pediatric patients that were followed prospectively. Over 70% had three or more whole-body MRIs. In our study, whole-body MRI detected 15 cancers, 86% of which were localized cancers that were treated with curative disease. And among 12 participants who had those 13 cancers, 10 were alive at data cut-off. These cancers included three lung cancers and four abdominal or pelvic sarcomas. Twenty-two cancers in our study were diagnosed with methods that were not whole-body MRI and those included some that are in the typical Li-Fraumeni spectrum like sarcomas, one lung cancer, and adrenocortical carcinoma. But many of those cancers were those that we would not expect to find with the whole-body MRI and were most commonly found because of symptoms. So our study shows that whole-body MRI is very important for the detection of asymptomatic cancers in individuals with Li-Fraumeni syndrome, and we think it supports its inclusion in guidelines and should be uniformly covered in the United States and elsewhere. It also shows that a multimodal surveillance program is critical for individuals with Li-Fraumeni syndrome and that we shouldn't over-rely on whole-body MRI and continue with the comprehensive screening program that we have in place, including being very keenly aware of symptoms and what patients are telling us. Our study shows that whole-body MRI for individuals with Li-Fraumeni syndrome contributes substantially to the detection of asymptomatic potentially curable cancers, and we think it should be covered uniformly by insurance and it supports the inclusion of whole-body MRI in guidelines. Our study also shows that it's critical to continue with multimodal surveillance, including other tests and being very aware of symptoms and what patients report. Lastly, our data show that further research in the early detection and interception of cancer for individuals with Li-Fraumeni is critical.

Related Videos

Hematologic Malignancies

Andrew Kuykendall, MD, on Hepcidin Mimetic for Polycythemia Vera

Andrew Kuykendall, MD, of Moffitt Cancer Center, discusses findings from the phase III VERIFY trial, which compared the efficacy of rusfertide vs placebo in patients with polycythemia vera who continue their current standard of care therapy (Abstract LBA3). 

Head and Neck Cancer

Stuart J. Wong, MD, on Adjuvant Regimen in Resected HNSCC

Stuart J. Wong, MD, of the Medical College of Wisconsin and Plenary discussant, reviews findings from the phase III NIVOPOSTOP randomized trial, which investigated the adjuvant use of nivolumab added to radiochemotherapy for patients with resected head and neck squamous cell carcinoma who are at high risk of relapse (LBA2). 

Breast Cancer

Hope S. Rugo, MD, FASCO, and Rebecca Alexandra Dent, MD, FASCO, on Breast Cancer Data Highlights: Sequencing of Endocrine Therapy

Hope S. Rugo, MD, FASCO, of City of Hope, and Rebecca Alexandra Dent, MD, FASCO, of National Cancer Centre Singapore, review the results of a biomarker analysis of the DESTINY-Breast06 trial, which evaluated trastuzumab deruxtecan after endocrine therapy in patients with metastatic breast cancer (Abstract 1013). They also discuss findings from the SERENA-6 and EMBER-3 trials, also presented at ASCO 2025, and what all this new data means for the sequencing of endocrine therapy in patients with breast cancer. 

Colorectal Cancer

Christopher M. Booth, MD, on a Structured Exercise Program for Patients With Colon Cancer

Christopher M. Booth, MD, of Queen’s University, reviews findings from the randomized phase III Canadian Cancer Trials Group (CCTG) CO.21 (CHALLENGE) trial, which evaluated the impact of a structured exercise program on disease-free survival in patients with stage III or high-risk stage II colon cancer (Abstract LBA3510). 

Genomics/Genetics

Angela R. Bradbury, MD, on Genetic Testing Approach in Patients With Metastatic Cancers

Angela R. Bradbury, MD, of the University of Pennsylvania, presents findings from the eREACH trial—a randomized study of an eHEALTH delivery alternative for cancer genetic testing for hereditary predisposition in patients with metastatic cancers (Abstract 10502).  

Advertisement

Advertisement




Advertisement